AUTHORS
Kieran Doran, Corvin Arveseth, BS2, Luana Chiquetto Paracatu, PhD3, Patrick Hunt4, Mia Warmka5, Ashley Jones, MS6, Laura Schuettpelz, MD, PhD7
AFFILIATIONS
1 Washington University in Saint Louis, Saint Louis, Missouri, United States
2 Washington University in Saint Louis, Saint Louis, Missouri, United States
3 Washington University in Saint Louis, Saint Louis, Missouri, United States
4 Washington University in Saint Louis, Saint Louis, Missouri, United States
5 Washington University in Saint Louis, Saint Louis, Missouri, United States
6 Washington University in Saint Louis, Saint Louis, Missouri, United States
7 Washington University in Saint Louis, Saint Louis, Missouri, United States
ABSTRACT
Loss of function mutations in DNA methyltransferase 3a (DNMT3A) are among the most common events in age-related clonal hematopoiesis, and predispose to the development of myeloid malignancies. Cardinal features of Dnmt3aKO hematopoietic stem cells (HSCs) include enhanced self-renewal capacity and resistance to inflammation-induced exhaustion, with prior studies showing that inflammation contributes to the clonal advantage of Dnmt3a mutant HSCs over their wild-type (WT) counterparts. However, the mechanisms by which Dnmt3a deficient HSCs resist inflammatory stress are not well understood.
We previously described the tetraspanin CD53 as a critical regulator of HSC quiescence in response to cell stress (Greenberg et al; Blood 2023). Upon inflammation or other proliferative stressors, CD53 is markedly upregulated in HSCs and contributes to the activation of the DREAM complex, a transcriptional repressive complex that inhibits the transcription of genes involved in cell cycling. Accordingly, Cd53-/- HSCs have a delayed return to quiescence following inflammatory stress, and their function is impaired with loss of repopulating and self-renewal capacities. Of note, previously published transcriptome data (Zhang et al; Nat Gen 2016) suggested that CD53 is overexpressed on Dnmt3a-deficient HSCs compared to WT. Given that Dnmt3a deficient HSCs are able to maintain quiescence and self-renewal capacity in the face of inflammatory stress (Zhang et al; Blood Cancer Disc 2022), we hypothesized that elevated CD53 activity promotes protective quiescence in Dnmt3a-deficient cells.
To explore the role of CD53 in Dnmt3a-deficient HSCs, we crossed Cd53-/- mice with Vav-Cre:Dnmt3afl/fl mice (Dnmt3aKO). We found that WT, Cd53-/-, Dnmt3aKO, and Cd53-/-Dnmt3aKO mice have no differences in either the number or frequency of hematopoietic stem and progenitor cells at baseline. Dnmt3aKO HSCs do, however, have a marked increase in CD53 expression compared to WT HSCs by confocal microscopy, consistent with transcriptome data. In addition, gene set enrichment analysis (GSEA) of a previously published dataset (GSE168807) revealed a significant downregulation of DREAM complex gene targets (indicating increased DREAM activity) in the Dmnt3a deficient HSCs, suggesting a potential role for CD53 and the DREAM complex in Dnmt3aKO HSCs. Indeed, serial MethoCult replating assays revealed that the enhanced self-renewal capacity of Dnmt3aKO over WT bone marrow was lost in the Cd53-/-Dnmt3aKO marrow, with Cd53-/-Dnmt3aKO cells failing to form colonies after the second replating while Dnmt3aKO cells continue to form colonies for multiple additional generations. Similarly, serial competitive transplantation of sorted HSCs demonstrated that the enhanced self-renewal of Dnmt3aKO HSCs in the bone marrow was lost in the absence of CD53, with Cd53-/-Dnmt3aKO HSCs failing to accumulate in the bone marrow of recipient mice unlike Dnmt3aKO HSCs. Importantly, Dnmt3aKO HSCs have been shown to maintain quiescence in response to acute in vivo interferon gamma (IFN-g) exposure, and this property was lost in the absence of CD53, with Cd53-/-Dnmt3aKO HSCs having significantly more cycling by Ki-67 staining than Dnmt3aKO HSCs following 48 hours of IFN-g treatment.
Taken together, these findings suggest that elevated CD53 promotes Dnmt3aKO HSC quiescence in response to inflammatory stress and facilitates their enhanced self-renewal capacity, nominating CD53 as a potential therapeutic target to mitigate Dnmt3a mutant -driven clonal hematopoiesis. Ongoing experiments are aimed at further elucidating the role of the DREAM complex in these processes.
DISCLOSURES
Kieran Doran: No relevant conflicts of interest to declare.